Imugene Limited Overview
Imugene Limited is a Sydney-headquartered, ASX-listed clinical-stage cell therapy company that, after a decade as a multi-platform immuno-oncology developer, has collapsed its pipeline onto a single asset: azercabtagene zapreleucel (azer-cel), an off-the-shelf allogeneic CD19 CAR T therapy in-licensed from Precision BioSciences in August 2023. Azer-cel is in a three-cohort Phase 1b basket study across ten US and five Australian sites, targeting CAR T-relapsed diffuse large B-cell lymphoma (DLBCL), CAR T-naïve B-cell malignancies, and patients progressing on BTK inhibitors. The asset carries three FDA Fast Track Designations (DLBCL post-CAR T; CLL/SLL; MZL). The company's investment case rests on high early response rates (82% ORR in CAR T-relapsed DLBCL; 79% in the CAR T-naïve cohort at ASCO 2026) set against acute balance-sheet fragility: A$2.6m cash at 30 June 2026, an A$105.3m FY2026 loss, a 34:1 consolidation, repeated deeply discounted raises, and an interim leadership structure after the CEO's July 2026 resignation.
Company's own description (FY2026 Annual Report). Imugene describes itself as a clinical-stage cell therapy company developing an off-the-shelf (allogeneic) CAR T therapy for blood cancers, stating that its lead and sole clinical program is azer-cel, a donor-derived CD19 CAR T that can be ready to administer within days rather than the three to six weeks required to manufacture conventional autologous CAR T from a patient's own cells. Its stated mission is to develop transformative cancer medicines to improve patients' lives, under the values of innovation, patient-centricity, relationships, integrity and excellence. The Directors' Report describes the Group as "an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers."
Independent characterisation. Imugene is best understood today as a capital-markets-funded, virtual development company holding an in-licensed late-Phase 1 cell therapy asset. It owns no manufacturing (its North Carolina cGMP facility was sold to Kincell Bio in April 2024, with Kincell now the contract manufacturer), runs a 14-person organisation, and outsources clinical execution to academic and community trial sites in the US and Australia. Value creation is entirely contingent on (i) generating registration-enabling clinical data, (ii) securing an FDA-agreed pivotal path (an FDA meeting in December 2025 reportedly validated dosing, population, endpoints and manufacturing readiness), and (iii) either licensing/partnering azer-cel with a large biopharma company or financing a pivotal study itself. The July 2026 placement included an unnamed international commercial-stage biopharmaceutical company subscribing ~14% of the placement, which management frames as a signal of strategic interest.
Business model and revenue model.
Operational footprint of the business model. The company's own accounts show the scale of de-risking via cost reduction: FY2026 payments to suppliers and employees fell A$35.7m (40%) to A$53.7m; employee benefits costs fell A$8.2m (45%); staff cash costs fell from A$20.5m to A$11.2m; executive headcount fell from 24 to 14 (FY2026 Annual Report, pp. 19–20, 32–33).
Strategy
Stated strategy themes (FY2026 Annual Report, verbatim themes).
-
"Our lead and sole clinical program is azer-cel" — single-asset focus.
-
Direct "capital and management attention toward the program with the strongest near-term potential to deliver for patients and shareholders."
-
Advance azer-cel "towards later-stage development" and "a registrational pathway."
-
Advance "discussions with major global pharmaceutical companies regarding strategic collaborations."
-
Maintain a lean cost base — "Imugene has continued to reduce its cost base and has significantly lowered its cash outflows."
Strategic initiatives register (last 24 months).
ESG/sustainability commitments: none disclosed. Medium-term financial targets/guidance: none disclosed beyond a runway statement — the July 2026 placement was said to extend funding "into calendar year 2027" (pro forma cash A$17.8m).
Products & Services
Imugene has no marketed products. The catalogue below covers every development asset, active and discontinued.
Azer-cel (azercabtagene zapreleucel) — ACTIVE, LEAD AND SOLE CLINICAL PROGRAM
| Attribute | Detail |
|---|---|
| Description | Off-the-shelf, allogeneic, donor-derived CAR T cell therapy targeting CD19 |
| Origin | Exclusive worldwide oncology licence from Precision BioSciences (Aug 2023); developed with Precision's ARCUS gene-editing platform† |
| Mechanism | Healthy-donor T cells engineered to express a CD19 CAR; expanded in large numbers for multiple patients; available "within days" vs. 3–6 weeks for autologous CAR T |
| Regimen | Lymphodepletion + azer-cel, with interleukin-2 (IL-2) in DLBCL cohort; concurrent BTKi in Cohort 3 |
| Target indications | DLBCL (incl. Richter's transformation), FL, CLL/SLL, MZL, WM, MCL, PCNSL |
| Trial | Phase 1b open-label multi-centre basket study; 10 US + 5 Australian sites |
| Patients dosed (cumulative, incl. Precision-era) | >130 patients dosed with azer-cel to date (FY2026 Annual Report) |
| Regulatory designations | FDA Fast Track: R/R DLBCL post-CAR T; R/R CLL/SLL and R/R MZL (June 2026) |
| Manufacturing | Kincell Bio (Research Triangle Park, NC) under manufacturing supply agreement; process/analytical development transferred to Kincell |
| Target customer | Haematologists at cell therapy-accredited centres; also potentially community settings given off-the-shelf logistics |
| Latest version / launch year | Investigational; no approval. Pivotal study pathway discussed with FDA (Dec 2025) |
| Pricing | Not applicable / not disclosed |
| Cohort | Population | Latest disclosed data | Date/Source |
|---|---|---|---|
| 1 — CAR T-relapsed DLBCL | DLBCL relapsed/refractory after autologous CAR T; ≥3 prior lines | ORR 82% (14/17): 7 CR, 7 PR | 1 Dec 2025; ASH 2025 oral |
| 2 — CAR T-naïve | Seven B-cell malignancies, 1–3 prior lines, no prior CAR T | ASCO 2026: ORR 79% (n=24 evaluable; 25 treated); 93% in 14 indolent patients; 0 Grade ≥3 CRS. By indication: DLBCL/RT 67% (n=6), MZL 83% (n=6), CLL 100% (n=4), PCNSL 50% (n=4), FL 100% (n=3), WM 100% (n=1) | 29 May 2026 (Dr Supriya Gupta, Univ. of Minnesota) |
| 3 — Concurrent BTKi | Progressed on BTKi | First patient dosed 28 May 2026; first CR (FL) 30 Jun 2026; CR in first MCL patient (1 Jul 2026); PR in second FL patient (27 Jul 2026); 5 patients dosed at report date | FY2026 Annual Report |
| Aggregate | All three cohorts | 44 evaluable: 19 CR + 17 PR (Aug 2026); 75% ORR across 55 patients (7 Oct 2026 announcement summary) | Chairman's letter; StockWire X |
Cohort-level data register.
CF33-hNIS (VAXINIA) — DISCONTINUED (FY2026)
Oncolytic chimeric orthopoxvirus (CF33) armed with the human sodium iodide symporter (hNIS) for imaging/radiotherapy combination, licensed from City of Hope†. Evaluated in the Phase 1 MAST trial in solid tumours, including bile tract cancer, with FDA Orphan Drug Designation recorded in the company's development table. Development ceased and assets impaired in FY2026.
CF33-CD19 (onCARlytics) — DISCONTINUED (FY2026)
Oncolytic virus engineered to express CD19 on solid-tumour cells, rendering them targetable by CD19 CAR T therapies (concept: "mark" solid tumours for blood-cancer CAR Ts). Phase 1 and IND achieved per company development table. Repositioned in H1 FY2026 via a collaboration with China-based JW Therapeutics; the proposed joint development was subsequently ceased.
HER-Vaxx (IMU-131) — INACTIVE
B-cell peptide vaccine inducing polyclonal anti-HER2 antibodies, studied in Phase 2 in HER2+ gastric cancer (HERIZON†) and the neoadjuvant IMPRINTER study (first patient June 2023, FY2023 Annual Report). Intangible's useful life reassessed in FY2026, leading to A$4.5m accelerated amortisation.
PD1-Vaxx — DISCONTINUED (FY2026)
B-cell peptide vaccine targeting PD-1 (Phase 1/2 in lung and colorectal settings†). Licence returned to Ohio State University.
Services
None. Imugene provides no commercial services.
Financial Narrative
Sources: FY2026 Annual Report (FY2026 audited; FY2025 restated; 1 July 2024 restated opening balance sheet; 5-year KPI table); FY2023 Annual Report (FY2022–FY2023 cash and net assets); StockAnalysis, Kalkine and InvestSMART (Morningstar) for FY2022–FY2024 income-statement and cash-flow line items as originally reported.
Income Statement
Notes and reconciliation:
-
FY2025 R&D shown at A$46.69m as originally reported (aggregator); restated FY2025 R&D is A$24.93m and restated operating loss A$49.18m (FY2026 Annual Report). FY2025 originally reported net loss was approx. A$69.0m (InvestSMART/Morningstar) vs. restated A$47.26m.
-
Statutory net loss after tax: FY2022 A$37.87m; FY2023 A$37.91m (Annual Report; Preliminary Final Report showed A$39.17m — discrepancy between preliminary and audited); FY2024 approx. A$149.7m (InvestSMART "after abnormals", originally reported) vs. A$157.6m total comprehensive loss in the company's own 5-year table; FY2025 A$47.26m (restated); FY2026 A$105.34m.
-
Gross profit, EBITDA and margins are not meaningful: no revenue. EBITDA is not reported; FY2026 operating loss includes A$20.2m impairment and A$4.5m accelerated amortisation, so EBITDA-equivalent loss is approx. A$81m before other depreciation (indicative only).
-
Revenue CAGR: not meaningful.
Commentary. The FY2022–FY2023 period reflects a multi-asset immuno-oncology company spending ~A$50m p.a. in operating expenses, partly offset by R&D Tax Incentive income. FY2024 is the inflection: the azer-cel acquisition, the build-out and subsequent sale of a US manufacturing facility (with an A$11.3m loss on asset disposal per StockAnalysis), and a three-program clinical slate drove the loss to its peak. FY2025 shows the first restructuring benefits, and the restatement — which removed a provision for future milestone-based expenses and recognised a A$28.2m non-cash gain in FY2025 — materially flatters the FY2025 comparative. FY2026's A$105.3m loss is dominated by non-cash and one-off items: A$20.2m impairments, the US$8m Precision milestone (expensed under the new policy), A$4.5m HER-Vaxx amortisation and a A$12.73m fair-value loss on the convertible notes within G&A. Management states that underlying R&D fell 3% and underlying G&A fell 42% year-on-year once these items are removed (FY2026 Annual Report, pp. 19–20).
Balance Sheet
FY2024 balance-sheet figures use the restated 1 July 2024 opening position; FY2023 net assets per audited Annual Report (Preliminary Final Report showed A$188.37m).
Convertible notes: face value reduced from A$20.0m (start of FY2026) to A$11.783m at 30 June 2026 via redemptions and refinancing; senior, unsecured, zero-coupon; maturity January 2030 (FY2026 Annual Report). Carrying value (A$6.18m) differs from face value; valuation basis per Note 12. Net tangible assets per security: 1.0 cent (30 June 2026) vs 11.1 cents (30 June 2025).
Commentary. The balance sheet has been almost entirely consumed. Cash fell 98% from the FY2023 peak; intangibles collapsed after the FY2026 impairments; working capital turned negative (–A$4.2m) at 30 June 2026 for the first time in the period reviewed, a condition relieved only by the July 2026 A$11.1m placement (pro forma cash A$17.8m per the placement announcement). Accumulated losses now exceed A$440m against A$427m of contributed capital.
Cash Flow
FY2022–FY2024 from Kalkine/StockAnalysis (Morningstar); FY2025–FY2026 audited. FY2026 free cash flow excludes the A$4.59m Azer-cel milestone (classified as investing).
Quarterly cash trajectory (Appendix 4C).
Discrepancy: Q4 FY2026 Appendix 4C reports A$2.510m cash at 30 June 2026 vs. A$2.630m in the audited accounts.
Ratios
Not meaningful for a pre-revenue company: ROIC, net debt/EBITDA, interest coverage, asset turnover, cash conversion cycle. Calculations are analyst-derived from figures above.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Other income (AUD Mn) | 4.97 | 4.45 | 2.09 |
Operating loss (AUD Mn) | -141.82 | -49.18 | -105.70 |
Loss before tax (AUD Mn) | -149.70 | -47.26 | -105.34 |
Capital Programmes
| Programme | Modality | Status (Oct 2026) | Accounting treatment |
|---|---|---|---|
Azer-cel | Allogeneic CD19 CAR T | Active — Phase 1b, 3 cohorts | Licence intangible; milestone expensed under new policy |
CF33-hNIS (VAXINIA) | Oncolytic virus | Discontinued FY2026 | Impaired (part of A$20.2m) |
CF33-CD19 (onCARlytics) | Oncolytic virus + CD19 CAR T | Discontinued (incl. JW Therapeutics collaboration) | Impaired (part of A$20.2m) |
HER-Vaxx | B-cell HER2 peptide vaccine | Inactive | Accelerated amortisation A$4.5m |
PD1-Vaxx | B-cell PD-1 peptide vaccine | Discontinued; licence returned to Ohio State University | — |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from ordinary activities (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Other income (AUD Mn) | 12.97 | 11.78 | 4.97 | 4.45 | 2.09 |
R&D expense as reported (AUD Mn) | 36.61 | 30.86 | 86.89 | 46.69 | 75.57 |
G&A expense (AUD Mn) | 14.06 | 20.43 | 59.91 | 27.82 | 31.86 |
Operating loss (AUD Mn) | -37.70 | -39.52 | -141.82 | -49.18 | -105.70 |
Total comprehensive loss attributable to owners (AUD Mn) | -37.85 | -38.13 | -157.63 | -48.02 | -105.96 |
Basic loss per share, post-consolidation (A$ cents) | 22.78 | 20.66 | 75.60 | 21.96 | 32.49 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Key Financials (AUD)
| Line item | FY2026 | FY2025 (restated) | Change |
|---|---|---|---|
Other income | 2,086,103 | 4,445,407 | -53% |
Other gains/(losses) | (365,530) | (876,341) | n/m |
Research and development expenses | (75,566,877) | (24,931,608) | +203% |
General and administrative expenses | (31,857,196) | (27,817,558) | +15% |
Operating loss | (105,703,500) | (49,180,100) | +115% |
Finance income | 492,153 | 2,081,324 | -76% |
Finance expenses | (125,477) | (163,075) | -23% |
Loss before income tax | (105,336,824) | (47,261,851) | +123% |
FX translation (OCI) | (623,157) | (760,384) | n/m |
Total comprehensive loss | (105,959,981) | (48,022,235) | +121% |
Basic and diluted LPS (AUD) | (0.32) | (0.22) | n/m |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 99.89 | 153.15 | 93.11 | 21.94 | 2.63 |
Intangible assets (AUD Mn) | 32.69 | 30.49 | 34.12 | 31.69 | 4.86 |
Net assets / total equity (AUD Mn) | 138.70 | 189.63 | 109.85 | 58.09 | 9.01 |
Balance Sheet (1 Jul 2024 (restated)–30 Jun 2026)
| Balance sheet detail (AUD Mn) | 1 Jul 2024 (restated) | 30 Jun 2025 (restated) | 30 Jun 2026 |
|---|---|---|---|
Total current assets | 113.03 | 41.74 | 9.82 |
Total non-current assets | 38.36 | 41.84 | 13.21 |
Total assets | 151.40 | 83.59 | 23.03 |
Trade and other payables | 7.81 | 11.72 | 6.26 |
Provisions (current) | 27.78 | 0.50 | 0.00 |
Convertible note (current, carrying value) | 0.00 | 9.25 | 6.18 |
Lease liabilities (current + non-current) | 1.28 | 1.40 | 0.11 |
Total liabilities | 41.54 | 25.50 | 14.02 |
Working capital (current assets less current liabilities) | 73.03 | 17.01 | -4.20 |
Total debt (convertible notes + leases) | 1.28 | 10.65 | 6.30 |
Short-term debt | 0.65 | 10.39 | 6.30 |
Long-term debt | 0.63 | 0.26 | 0.00 |
Net debt / (net cash) | -91.83 | -11.29 | 3.67 |
Goodwill | 0.00 | 0.00 | 0.00 |
Issued capital | 370.31 | 380.68 | 427.27 |
Accumulated losses | -298.22 | -339.37 | -440.87 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -30.85 | -31.47 | -101.73 | -75.57 | -44.74 |
Free cash flow (AUD Mn) | -31.11 | -31.47 | -108.80 | -83.12 | -44.74 |
Financing cash flow (AUD Mn) | 101.34 | 82.98 | 49.43 | 17.37 | 29.87 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
FY2026 vs FY2025 cash flow detail (AUD Mn)
| FY2026 vs FY2025 cash flow detail (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Payments to suppliers and employees | -89.45 | -53.75 |
R&D Tax Incentive received | 11.11 | 8.51 |
Interest received | 2.37 | 0.49 |
Capex (PP&E) | -7.55 | 0.00 |
Payments for azer-cel assets / milestones | -6.91 | -4.59 |
Proceeds from share issues | 0.00 | 40.94 |
Convertible note issued / (redeemed) | 20.00 | -7.38 |
Share issue costs | -1.32 | -2.67 |
Cash Flow (Quarterly)
| Metric | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|
Quarter-end cash (AUD Mn) | 14.10 | 5.96 | 2.51 |
Net operating cash used (AUD Mn) | — | 9.67 | 9.21 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE (total comprehensive loss / avg equity, %) | -23 | -105 | -57 | -316 |
ROA (net loss / avg total assets, %) | not computable | not computable | -40 | -198 |
Current ratio (x) | — | 2.83 | 1.69 | 0.70 |
Debt / equity (x) | — | 0.01 | 0.18 | 0.70 |
Geography Overview
| Geography | Activity | FY2026 indicator |
|---|---|---|
United States | Clinical sites, CMO function, manufacturing (Kincell, NC), FDA engagement | 10 of 15 trial sites |
Australia | HQ (Sydney), Board, CFO, R&D Tax Incentive claims, trial sites | 5 of 15 trial sites; A$2.7m FY2025 R&D refund |
China | JW Therapeutics onCARlytics collaboration | Ceased FY2026 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at year end (AUD) | 6.12 | 3.06 | 2.04 | 0.442 | 0.115 |
Share price high (AUD) | 21.42 | 10.88 | 5.10 | 2.72 | 0.46 |
Share price low (AUD) | 4.42 | 2.72 | 1.36 | 0.34 | 0.09 |
Market capitalisation 30 June (AUD Mn) | 1,056 | 584 | 409 | 97 | 48 |
Valuation Multiples
| Multiple | Imugene | Comment |
|---|---|---|
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Nil revenue |
P/B | ~2x (indicative) | ~A$40m market cap vs ~A$20m pro forma equity (A$9.0m + A$11.1m raise) |
EV (indicative) | ~A$35–40m | Market cap + A$11.8m note face value – ~A$13–18m pro forma cash (estimate) |
Share Price & Returns
| Date | Instrument | Amount (AUD Mn) | Price (AUD) | Attaching securities |
|---|---|---|---|---|
Jul 2025 | Placement + SPP | 24.92 | 0.33 | 3 options per 4 shares, ex. A$0.43, piggyback ex. A$0.86 (exp. 30 Jun 2028) |
Mar 2026 | Placement + SPP | 16.00 | 0.18 | 1:1 options ex. A$0.18, piggyback ex. A$0.30 (exp. 30 Jun 2029) |
Jul 2026 | Two-tranche placement | 11.12 | 0.095 | None disclosed |
Capital Instruments
| Instrument | Face value (AUD Mn) | Coupon | Maturity | Holder |
|---|---|---|---|---|
Senior unsecured zero-coupon convertible notes | 11.783 (30 Jun 2026) | 0% | January 2030 | CVI Investments, Inc. |
New convertible notes (Aug 2026 roll) | 2.1 (replacing existing notes) | 0% | — | CVI Investments, Inc. |
Warrants (Aug 2026) | Up to 1.68 if exercised | — | — | CVI Investments, Inc. |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance. No financial guidance. Management states that azer-cel is not expected to generate revenue in the short term; that July 2026 funding extends runway into calendar 2027; and that proceeds support Phase 1b expansion, regulatory engagement, manufacturing scale-up and partnering discussions. The FY2026 Directors' Report states that, pending successful development, azer-cel "could increase shareholder value by many multiples."
Consensus growth expectations. None available (pre-revenue; no reliable consensus).
Bull case.
-
Clinical signal is consistent across cohorts: 82% ORR post-CAR T DLBCL, 79% ORR CAR T-naïve, and early CRs in BTKi-refractory FL and MCL — supporting a broad label strategy.
-
Regulatory scaffolding is in place: three Fast Track Designations and an FDA meeting validating pivotal design elements shorten the path to a registrational study and potential Accelerated Approval.
-
Valuation asymmetry: at ~A$40m market cap, any partnering deal with a global biopharma (one already participated in the July placement) could re-rate the stock materially relative to the remaining Precision milestones.
Bear case.
-
Funding is existential: A$2.6m cash at year end, ~A$9m quarterly operating burn in H2 FY2026, and a pivotal trial unfunded — further heavy dilution is highly probable.
-
Data are small, single-arm and immature: many subgroup response rates rest on 1–6 patients; durability versus approved autologous CAR T and bispecifics is unproven.
-
Execution and governance risk: no CEO, a new CMO, a second-strike remuneration history, and serial program write-downs (A$20.2m impairment) that question prior capital allocation.
Key catalysts and monitorables (next 12 months).
Concluding analyst verdict.
Imugene in October 2026 is a fundamentally different company from the A$1bn multi-platform immuno-oncology story of 2022. Through write-offs, divestment and restructuring, it has become a 14-person, single-asset allogeneic CAR T developer whose entire enterprise value hangs on azer-cel. The clinical data are genuinely encouraging for an off-the-shelf CD19 product: an 82% response rate in DLBCL patients who have already failed autologous CAR T, a 79% response rate in CAR T-naïve B-cell malignancies with no high-grade cytokine release syndrome at ASCO, and complete responses in the first evaluable BTKi-refractory patients. Three Fast Track Designations and a constructive FDA meeting give the program a credible regulatory scaffold, and the hiring of a CMO with direct allogeneic pivotal experience is a sensible fit.
The balance sheet, however, overwhelms the science in the near term. The company ended FY2026 with A$2.6m cash and negative working capital, relying on a A$11.1m placement at a ~30% discount to reach calendar 2027. Raise prices fell from A$0.33 to A$0.095 within twelve months, a convertible note overhang remains to 2030, and Precision is owed milestones and royalties on any success. Leadership is interim, and shareholders delivered a second strike on pay in 2025.
Our assessment is that Imugene is a high-risk, binary option on a partnering or licensing transaction. The early data are strong enough to attract strategic interest — as the biopharma participation in the July raise suggests — but small samples and short follow-up leave durability unproven against well-funded allogeneic rivals and approved bispecifics. Absent a partner, a self-funded pivotal trial implies dilution on a scale that could largely transfer any clinical upside to new capital providers. Investors should treat the next two to three quarters — CEO appointment, ASH 2026 updates and any partnering news — as decisive, and size exposure accordingly.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | FY2026 total remuneration (A$, incl. share-based) |
|---|---|---|---|---|
Paul Hopper | Executive Chairman (overseeing leadership pending CEO appointment) | Director since 31 Oct 2012 | 20+ years managing and funding biotech/healthcare companies in Australia and the US; director of Radiopharm Theranostics (ASX: RAD); former director Chimeric Therapeutics (until 25 Nov 2025) | 463,366 |
Darren Keamy | Chief Financial Officer and Company Secretary | Since 4 Mar 2025 | CFO and Company Secretary, Clinuvel Pharmaceuticals (2005–2024) | 623,216 |
Dr John Le Gall, MD MBA | Chief Medical Officer | Since 7 Oct 2026 | Allogene Therapeutics — redesigned pivotal development plan for cema-cel (allogeneic CD19 CAR T) | — |
CEO | Vacant | Since 24 Jul 2026 | Search commenced July 2026 | — |
“—” = not publicly disclosed.
Executive Leadership Team (FY2026 remuneration (AUD))
| Name | Role | Departure | Context | FY2026 remuneration (AUD) |
|---|---|---|---|---|
Leslie Chong | CEO & Managing Director | 24 Jul 2026 (announced 27 Jul) | Personal reasons; ~11 years' service; six months' salary cessation payment; 170,404 unvested performance rights accelerated | 1,616,117 |
Dr John Byon | Chief Medical Officer | Oct 2026 | Mutual agreement; remains consultant; role restructured for single-asset company | 1,899,603 |
Dr Bradley Glover | Chief Operating Officer | 2 Jan 2026 | To focus on other business interests | -40,649 (reflects share-based payment reversal) |
Dr Paul Woodard | Former executive (FY2025 KMP) | FY2025 | — | 741,102 (FY2025) |
Mike Tonroe | Former CFO | FY2025 | Replaced by Darren Keamy | 244,116 (FY2025) |
Dr Monil Shah | Former executive (FY2025 KMP) | FY2025 | — | 740,211 (FY2025) |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary & fees | Cash bonus | Leave | Super / 401k | Total cash |
|---|---|---|---|---|---|
Paul Hopper | 260,100 | 75,249 | — | — | 335,349 |
Leslie Chong | 787,950 | 163,500 | 7,638 | 30,000 | 989,088 |
Darren Keamy | 355,250 | 151,344 | 12,513 | 30,000 | 549,107 |
Dr John Byon | 695,580 | 286,381 | 54,206 | 43,826 | 1,079,993 |
Dr Bradley Glover | 382,665 | — | -89,293 | — | 293,372 |
Kim Drapkin (NED) | 88,856 | — | — | — | 88,856 |
Dr Jakob Dupont (NED) | 81,478 | — | — | — | 81,478 |
Dr Lesley Russell (NED) | 74,042 | — | — | — | 74,042 |
Total KMP | 2,725,921 | 676,474 | -14,936 | 103,826 | 3,491,285 |
Board of Directors
| Name | Role | Appointed | Independence | Committees | Background | Other boards |
|---|---|---|---|---|---|---|
Paul Hopper | Executive Chairman | 31 Oct 2012 | Not independent (executive) | — | Biotech capital markets, chair/CEO roles AU & US | Radiopharm Theranostics |
Dr Lesley Russell | NED | 23 Apr 2019 | Independent | Rem & Nom (member); Audit & Risk (member) | Haematologist/oncologist; former CMO with multiple FDA/EMA approvals | Chimeric Therapeutics; Enanta Pharmaceuticals |
Dr Jakob Dupont | NED | 7 Sep 2022 | Independent | Rem & Nom (Chair); Audit & Risk (member) | Oncology drug developer; Executive Venture Partner, Sofinnova Investments | Pyxis Oncology; Bolt Biotherapeutics |
Kim Drapkin | NED | 21 Jun 2023 | Independent | Audit & Risk (Chair); Rem & Nom (member) | 25+ years biotech finance leadership | Acumen Pharmaceuticals; LENZ Therapeutics |
Dr Charmaine Gittleson | NED | 30 Jun 2026 | Independent | None yet | Former CMO, CSL Limited; 20+ years drug development and regulatory | Chair, Percheron Therapeutics; PolyNovo; George Medicines |
Michael Kotsanis | NED | 30 Jun 2026 | Independent | None yet | 35 years pharma operations; former CEO Acrux | ICE Pharma (private) |
Major Shareholders
| Holder | Shares (post-consolidation) | Basis |
|---|---|---|
Paul Hopper | 12,266,512 | KMP holdings, 30 Jun 2026 |
Leslie Chong (former CEO) | 3,483,806 | At 30 Jun 2026 |
Dr Lesley Russell | 624,651 | 30 Jun 2026 |
Dr Bradley Glover (former) | 245,233 | At cessation |
Dr John Byon (former) | 244,600 | 30 Jun 2026 |
Kim Drapkin | 32,914 | 30 Jun 2026 |
Dr Jakob Dupont | 32,038 | 30 Jun 2026 |
Total KMP | 16,929,754 | ~4% of ~425m shares (indicative) |
Competitive Landscape
Key Competitors
| Competitor | Segment | Product(s) | Relative positioning vs azer-cel | Revenue / scale |
|---|---|---|---|---|
Gilead / Kite | Autologous CD19 CAR T | Yescarta, Tecartus | Approved standard; manufacturing lag 2–4+ weeks | — |
Bristol Myers Squibb | Autologous CD19 CAR T | Breyanzi | Approved across DLBCL, FL, CLL, MCL, MZL | — |
Novartis | Autologous CD19 CAR T | Kymriah | Approved; mature | — |
Allogene Therapeutics | Allogeneic CD19 CAR T | Cema-cel (ALLO-501A) | Most direct allogeneic comparator; pivotal-stage consolidation strategy | Pre-revenue |
CRISPR Therapeutics | Allogeneic CD19 CAR T | CTX112 | Gene-edited allogeneic competitor | Pre-product revenue in oncology |
Caribou Biosciences | Allogeneic CD19 CAR T | CB-010 | Allogeneic competitor in LBCL | Pre-revenue |
Roche (incl. Poseida) | Allogeneic CAR T; bispecifics | P-CD19CD20-ALLO1; Columvi, Lunsumio | Big-pharma resources across modalities | Large-cap |
AbbVie / Genmab | Bispecific | Epkinly (epcoritamab) | Off-the-shelf alternative already approved | Large-cap |
Autolus | Autologous CD19 CAR T | Obe-cel (Aucatzyl) | Differentiated autologous | Early commercial |
Arovella Therapeutics (ASX: ARL) | Allogeneic CAR-iNKT | ALA-101 (CD19) | ASX peer, earlier stage | Pre-revenue |
Chimeric Therapeutics (ASX: CHM) | CAR T / NK | CHM CDH17, CORE-NK | ASX cell therapy peer | Pre-revenue |
BTKi incumbents (AbbVie/J&J, AstraZeneca, BeiGene) | Small molecules | Imbruvica, Calquence, Brukinsa | Partner/combination opportunity rather than pure competitor | Large-cap |
Competitor Detail
| Metric | Imugene (FY2026) |
|---|---|
Revenue | A$0 |
Lead allogeneic CD19 stage | Phase 1b (3 FTDs) |
Cash at latest period | A$2.6m (Jun 2026); ~A$17.8m pro forma |
R&D intensity | 70% of opex |
Recent Developments
--



